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Acute phase reaction (APR) can be defined as a complex 
response of the organism to an endogenous or exogenous 
stimulus inducing systemic inflammation. APR can be trig-
gered by several pathological causes such as infections, 
traumas, myocardial infarction, connective tissue disorders 
and malignancies (1). During APR, several systemic and 
metabolic alterations occur, such as fever onset and eleva-
tion of erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP). Also among the changes are increased se-
rum levels of acute phase proteins such as fibrinogen, ferri-
tin, serum amyloid A (SAA), -2 globulins, and haptoglobin, 
as well as decreased serum albumin levels (1).
During APR, serum lipid profile undergoes typical modi-
fications including reduced HDL-cholesterol (HDL-C) levels, 
often associated with total and LDL-cholesterol (LDL-C) 
decrease, and increase or no change in triglycerides (TGs) 
(2). The mechanisms underlying HDL-C serum level de-
crease during inflammation, likely to be multiple, are not 
entirely known. For example, it has been suggested that a 
reduction of liver ApoA-I secretion and an increase in en-
dothelial lipase or phospholipase A2 expression may have 
a role (3). An alteration of plasma lipid profile may also 
derive from an inadequate balance between endogenous 
synthesis, absorption from gut, and clearance (4). To date, 
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no studies have evaluated whether an imbalance between 
cholesterol synthesis and absorption underlies HDL level 
reduction during APR.
During systemic inflammation, HDL particles undergo 
profound variations in terms of structure and composition. 
Some HDL components, such as ceruloplasmin and SAA, 
increase proportionally to the degree of inflammation 
(5, 6), whereas other molecules, such as paraoxonase 1, 
decrease (7). Finally, HDL functional properties are modi-
fied in APR, with a shift from an anti- to a pro-inflammatory 
phenotype (8). Among the protective functions of HDL is 
their cholesterol efflux capacity (CEC). Cell cholesterol 
efflux is the first limiting step of reverse cholesterol trans-
port, the process promoting the transfer of excess choles-
terol from peripheral tissues to the liver for final excretion 
(7, 9–11). HDL CEC has recently been proposed as a car-
diovascular risk marker (12). Indeed, HDL CEC impair-
ment has been described in inflammatory-based diseases 
such as rheumatoid arthritis, psoriasis, and systemic lupus 
erythematosus (13–15). Atherosclerosis itself is an inflam-
matory disease and its predisposing conditions, such as dia-
betes, obesity, and metabolic syndrome, are associated with 
a low-grade subclinical inflammation (16, 17).
Thus, the modifications in serum lipids associated to 
APR, particularly those regarding HDL structure, composi-
tion, and capacity to maintain cell cholesterol homeostasis, 
could explain at least in part the link between inflam-
mation and atherosclerosis. Epidemiological studies have 
shown that patients suffering from chronic infections 
(1, 18, 19) or chronic inflammatory diseases, including 
rheumatoid arthritis (20), psoriasis (21), and systemic lu-
pus erythematosus (22) have increased cardiovascular risk 
not fully explained by the traditional risk factors.
The aim of this work was to verify whether an unbalance 
between cholesterol synthesis and absorption associates 
with lipid profile changes in subjects with APR related to 
infections, oncologic causes, or autoimmune diseases. In 
addition, we evaluated whether APR is characterized by 
alterations of HDL structure, composition, and cell cho-
lesterol efflux-promoting function. Finally, we looked for a 
possible relationship between HDL-related parameters, in-
flammatory status, and plasma markers of cholesterol 
homeostasis.
MATERIALS AND METHODS
Study subjects
We examined 59 subjects (39 males and 20 females, aged be-
tween 19 and 83 years old) who referred to the Internal Medicine 
Department of Perugia General Hospital and presented serum 
CRP levels >1.5 mg/dl. Laboratory parameters, including ESR, 
ferritin, white blood cells (WBCs), and external body tempera-
ture of the APR group, are shown in Table 1. APR was caused by 
infections (n = 37), oncologic causes (n = 8), and autoimmune 
diseases (n = 14). Among infections were erysipelas, infected 
wounds, pneumonia, urinary tract infections, abscesses, and pel-
vic infections. Oncologic causes included lymphoma and colon, 
pancreas, lung, or oral carcinomas. Patients with autoimmune 
diseases presented rheumatoid arthritis, systemic lupus erythema-
tosus, Still disease, ulcerative colitis, Crohn’s disease, polymyalgia 
rheumatica, ankylosing spondylitis, sarcoidosis, and overlap syn-
drome. Among APR subjects, the prevalence of cardiovascular 
disease-related conditions was 14.3% for type-2 diabetes, 32.1% 
for hypertension, and 25% for coronary heart disease. A control 
group of 39 subjects (11 males and 28 females, aged between 22 
and 81 years old) who referred to the Internal Medicine Depart-
ment of Perugia General Hospital without APR was included in 
the study. Laboratory parameters, including ESR, ferritin, WBCs, 
and external body temperature of the control subjects are shown 
in Table 1. This group included subjects with anxiety or depres-
sion, epilepsy, migraine, kidney gallstones without infection, osteo-
porosis, and hypertension. Among control subjects, the prevalence 
of cardiovascular disease-related conditions was 12.5% for type-2 
diabetes, 43.2% for hypertension, and 10.8% for coronary heart 
disease.
To exclude the potential effect of the poor matching in terms 
of age and sex between APR patients and controls (Table 1), all 
of the statistical analyses were adjusted for these two parameters. 
Both P-values from unadjusted and adjusted analyses are reported 
in the Results section. Subjects taking medications interfering 
with lipid metabolism were excluded from the study. All subjects 
underwent clinical examination. BMI was defined as weight (kg)/
squared height (m2). Blood pressure was measured in triplicate by 
TABLE 1. Clinical and laboratory parameters of control and APR subjects
Control Subjects APR Subjects P
P Adjusted for Age 
and Gender
Age (y) 59 ± 15 63 ± 16 0.088 N/A
BMI 25.77 ± 4.97 24.59 ± 4.92 0.407 0.496
SBP (mmHg) 133.19 ± 17.95 125.49 ± 18.47 0.033 0.009
DBP (mmHg) 78.42 ± 10.72 75.09 ± 11.34 0.218 0.123
CRP (mg/dl) 0.1 (0.1–0.3)a 6 (2–15.7)a <0.001 <0.001
ESR (mm/h) 22.18 ± 16.94 64.72 ± 33.75 <0.001 <0.001
WBC (×103/mmc) 7.55 ± 2.56 9.89 ± 5.26 0.010 0.016
Ferritin (ng/ml) 56.6 (24–96)a 185.4 (61.5–592.4)a <0.001 0.0007
Temperature (°C) 36.30 ± 0.64 37.34 ± 1.07 <0.001 <0.001
Glicemia (mg/dl) 94.67 ± 21.50 95.26 ± 27.25 0.853 0.742
Insulinemia (mUI/l) 7.4 (5.4–10.6)a 4.4 (3.2–6.5)a 0.003 0.049
HOMA-IR (computer-based calculation) 1.01 (0.72–1.48) 0.64 (0.45–0.97) 0.480 0.100
Normally distributed data are expressed as mean ± SD; the nonparametric Mann-Whitney test was used to 
compare the two groups. P-values adjusted for age and gender were obtained by general linear models. P-values 
expressing significant differences are shown in bold. DBP, diastolic blood pressure; SBP, systolic blood pressure; 
HOMA-IR, Homeostasis Model Assessment-Insulin Resistance index; N/A, not applicable.
a Skewed data are expressed as median (interquartile range).
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a physician with a mercury sphygmomanometer and a brachial 
cuff of appropriate size placed around the nondominant arm. 
Blood samples were drawn within 24 h from admission. CRP, ESR, 
WBC count, and ferritin were evaluated with an automated ana-
lyzer. Glycemia and serum insulin were evaluated by ELISA. The 
Homeostasis Model Assessment of Insulin Resistance was calcu-
lated with a computer-based model (23).
The study was performed in accordance with the ethical prin-
ciples set in the Declaration of Helsinki for experiments involving 
humans. The study protocol received approval from the local 
ethical committee. Written informed consent was obtained from 
all study participants.
Lipid profile
Total cholesterol (TC), HDL-C, and TG were measured with an 
enzymatic colorimetric method. For HDL-C, the method was 
applied after precipitation of apoB-containing lipoproteins with 
polyethylene glycol (PEG). LDL-C was calculated by the Friedewald 
formula. apo AI and B were measured by immune nephelometry.
Cholesterol synthesis and absorption
The quantification of plasma noncholesterol sterols, i.e., la-
thosterol, sitosterol, and campesterol, allows the estimate of cho-
lesterol synthesis and absorption. Lathosterol is considered a 
surrogate marker of cholesterol synthesis; campesterol and sitos-
terol are surrogate markers of cholesterol absorption (24).
Plasma lathosterol, campesterol, and sitosterol were measured 
by gas chromatography coupled to mass spectrometry with multi-
ple selected ion monitoring, according to the protocol of Ahmida 
et al. (25). This procedure measures TC, lathosterol, campesterol, 
and sitosterol in the same run. The test on the procedure repro-
ducibility, run with 10 samples in the same day for several days, 
showed coefficients of variation ranging from 1.5% to 2.4% within 
1 day and from 2.8% and 3.4% among days. Noncholesterol ste-
rols were standardized and expressed as ratios to cholesterol 
(mmol/mmol), to exclude the effect of different cholesterol levels, 
unless otherwise specified.
HDL composition and subclasses
The plasma concentration of HDL particles containing only 
apoA-I (LpA-I) and that of particles containing both apoA-I and 
apoA-II (LpA-I:A-II) was determined by electroimmunodiffusion 
in agarose gel (Sebia Italia). HDL distribution according to size 
was determined by nondenaturing polyacrylamide gradient gel 
electrophoresis of the d < 1.21 g/ml plasma total lipoprotein frac-
tion (26). HDL subclasses were divided into three size intervals: 
small (diameter 7.2–8.2 nm), medium (diameter 8.2–8.8 nm), 
and large (diameter 8.8–12.7 nm) HDL. The protein-stained gels 
were scanned with an imaging densitometer and protein content 
evaluated separately for each HDL subclass. HDL subclasses 
were also analyzed by nondenaturing 2D-electrophoresis fol-
lowed by immunodetection with a commercial polyclonal anti-
body against human apoA-I (Calbiochem) (27). Serum content 
of pre-migrating HDL was expressed as percentage of total 
apoA-I signal.
HDL CEC
HDL CEC was measured in a subgroup of APR patients (n = 24) 
and control subjects (n = 25). Patient subset was representative 
of the main group in terms of APR causes (14 infectious, 4 onco-
logic, and six autoimmune). HDL CEC was evaluated through 
widely validated isotopic techniques by using specific cellular 
models to allow the analysis of the main pathways of cell cho-
lesterol efflux to HDL. First, J774 murine macrophages (J774 
A.1, from ATCC) in basal conditions were used as a model of 
cholesterol aqueous diffusion (AD); J774 cells incubated with 0.3 
mM of a cAMP analog (cpt-cAMP, Sigma-Aldrich, Milano, Italy) to 
induce ABCA1 expression, were used as a model of total CEC as 
previously described (28, 29). The net contribution of ABCA1-
mediated cholesterol efflux was calculated as the difference be-
tween total CEC and AD-CEC (30). Rat hepatoma Fu5AH cells, 
in the absence or presence of a specific SR-BI inhibitor (Block 
Lipid Transfer-1 10 M, ChemBridge, San Diego, CA), were used 
to evaluate SR-BI-mediated cholesterol efflux (31). CHO cells, 
transfected or not with the human ABCG1 gene, were used to 
evaluate ABCG1-mediated cholesterol efflux. The specific ABCG1 
contribution was calculated as the difference between CEC in 
ABCG1-transfected and nontransfected cells (32). In all assays, 
the cells were initially labeled with [1,2-3H]cholesterol (Perki-
nElmer, Milano, Italy) for 24 h in the presence of an ACAT inhibi-
tor to keep all cholesterol in the unesterified form. After an 
equilibration period in medium containing 0.2% BSA (BSA, 
Sigma-Aldrich), cells were exposed for 4 h to 2% HDL serum frac-
tions for SR-BI, total, AD, and ABCA1-mediated CEC, and for 6 h 
to 1% HDL serum fractions for ABCG1-mediated CEC. Serum 
HDL fractions were obtained from whole serum by precipitation 
of the apoB-containing lipoproteins with PEG, as previously de-
scribed (33). HDL CEC was expressed as a percentage of the ra-
dioactivity released into the medium over the total radioactivity 
incorporated by cells. A pool of human normo-lipidemic sera was 
tested in each assay as reference standard 1 and its CEC was used 
to normalize the patient samples values from different experi-
ments to correct for the inter-assay variability. A second pool of 
human normo-lipidemic sera as reference standard 2 was tested 
in each assay and its CEC, after normalization, was the index of 
the intra-assay variability.
SAA content in HDL
To evaluate SAA content in the HDL fraction, sera were de-
pleted of the apoB-containing lipoproteins by precipitation with 
PEG (34). SAA was measured by ELISA assay (Novex by Life Tech-
nologies, Frederick, MD) in the same subset of samples analyzed 
for HDL CEC (n = 24 APR and n = 25 controls).
Statistical analysis
Data are reported as mean ± SD. Variables with skewed dis-
tribution (TG, CRP, ferritin, insulinemia, Homeostasis Model 
Assessment-Insulin Resistance index, and SAA) are reported 
as median and interquartile range and log-transformed before 
analysis. Univariate comparisons between APR and controls were 
performed by two-sided nonparametric Mann-Whitney test. 
Multivariate comparisons adjusted for age and sex were performed 
by general linear models. CEC results were further adjusted for 
HDL-C levels. Comparison of values among the three subgroups 
of APR causes (infectious, oncologic, and autoimmune) was per-
formed by Kruskal-Wallis test. Associations between variables were 
assessed by Spearman correlation. P-values below 0.05 were con-
sidered as significant. All analyses were performed using the SAS 
Statistical package v. 9.4 (SAS Institute Inc.).
RESULTS
Detailed characteristics of patients and controls are re-
ported in Table 1. Patients displayed a moderate increase 
in typical APR-defining parameters, which were signifi-
cantly higher as compared with controls: CRP (mean + 
19.5-fold, P < 0.001), ESR (mean + 2.9-folds, P < 0.001), WBCs 
(mean + 1.3-fold, P < 0.01), ferritin (mean + 6-fold, P < 0.001), 
and temperature (mean + 1.03-fold, P < 0.001) (Table 1).
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Statistical analyses without and with adjustment for age 
and gender provided similar results. CRP levels were sig-
nificantly different across the three groups of diagnoses 
(supplemental Table S1). In particular, infections were as-
sociated with higher CRP values compared with other diag-
noses (mean + 1.95-fold and + 1.96-fold vs. autoimmune 
and oncologic causes, respectively). Conversely, we did not 
observe differences across diagnosis in the other inflamma-
tory parameters examined.
Lipid profile
APR subjects showed an altered serum lipid profile char-
acterized by reduced TC (29.7%), LDL-C (31.6%), and 
HDL-C (43.7%) (Table 2). TG did not differ between the 
two groups. ApoA-I levels were markedly lower in APR sub-
jects (35.1%), whereas apoB levels were only slightly and 
nonsignificantly decreased compared with controls (Table 2). 
Analyses without and with adjustment for age and gender 
provided the same results. Stratifying patients according 
to the etiopathogenesis of APR, we did not detect signifi-
cant differences in lipid changes except for lower apoA-I 
levels in infectious compared with oncologic conditions 
(mean – 28.5%, supplemental Table S2).
Cholesterol synthesis and absorption
As shown in Table 3, no difference was detected between 
APR and control groups in plasma markers of cholesterol 
synthesis and absorption, expressed as ratios over choles-
terol. Similarly, we did not find differences in the ratio 
campesterol/lathosterol parameter that simultaneously re-
flects absorption and synthesis. Analyses without and with 
adjustment for age and gender provided the same results. 
In addition, no differences were found across the three 
groups of causes of APR (supplemental Table S3).
HDL composition and size
Looking in detail at the HDL particles composition and 
size, we found that both LpA-I and LpAI:AII were signifi-
cantly reduced in APR subjects compared with controls, 
with a greater reduction for LpAI:AII (28% and 44.8% 
for LpA-I and LpA-I: A-II, respectively, Table 4). Percent-
age of small and large HDL did not differ between the two 
groups. Conversely, medium-sized HDL particles were slightly 
but significantly reduced in inflamed subjects (10.5%). 
Pre HDL content was lower in APR subjects (26%; 
Table 4). The same results were obtained analyzing data 
without and with adjustment for age and gender except for 
the difference in pre HDL levels, which was lost after 
adjustment. Stratifying APR patients based on the diagno-
sis, we found a trend toward significant difference across 
groups in terms of LpA-I:A-II and a significant difference in 
pre HDL (supplemental Table S4). In particular, APR 
due to infections associated with the lowest levels of both 
LpA-I:A-II (mean  37% and  17.3% vs. autoimmune and 
oncologic causes, respectively) and pre HDL (mean  
57.7% and  66.7% vs. autoimmune and oncologic causes, 
respectively).
HDL CEC
We next evaluated HDL CEC based on previous obser-
vations of compromised HDL functional properties in in-
flammatory conditions (13, 14, 34, 35). We measured serum 
HDL CEC by distinguishing between the main cell cho-
lesterol efflux pathways in 24 subjects with APR and 25 con-
trols. As shown in Fig. 1A, cholesterol efflux from cAMP- 
stimulated J774 macrophages (total CEC) was significantly 
lower in APR subjects compared with controls (18%). 
Such difference persisted after adjustment for age, gender, 
and HDL-C levels (Model 3, Table 5). Separately analyzing 
TABLE 2. Serum lipid profiles of control and APR subjects
Control Subjects APR Subjects P P Adjusted for Age and Gender
TC (mg/dl) 194.25 ± 43.65 136.53 ± 37.59 <0.001 <0.001
LDL-C (mg/dl) 120.60 ± 36.36 82.50 ± 29.60 <0.001 <0.001
HDL-C (mg/dl) 52.20 ± 19.17 29.40 ± 11.38 <0.001 <0.001
TG (mg/dl) 100.5 (67.5–131.5)a 103.5 (77–150)a 0.186 0.190
apoA-I (mg/dl) 129.94 ± 30.92 84.03 ± 29.85 <0.001 <0.001
apoB (mg/dl) 73.85 ± 15.13 68.06 ± 20.35 0.139 0.795
Normally distributed data are expressed as mean ± SD; the nonparametric Mann-Whitney test was used to 
compare the two groups. P-values adjusted for age and sex were obtained by general linear models. P-values 
expressing significant differences are shown in bold.
a Skewed data are expressed as median (interquartile range).
TABLE 3. Non-cholesterol plasma sterols in control and APR subjects
Control Subjects APR Subjects P
P Adjusted for Age 
and Gender
Lathosterol (102 mol/mmol cholesterol) 109.19 ± 57.71 106.95 ± 67.51 0.727 0.883
Campesterol (102 mol/mmol cholesterol) 36.05 ± 19.57 33.85 ± 20.07 1.000 0.465
Sitosterol (102 mol/mmol cholesterol) 92.59 ± 56.53 82.13 ± 42.49 0.793 0.351
Campesterol/lathosterol ratio 0.51 ± 0.61 0.52 ± 0.59 0.872 0.656
Sitosterol/lathosterol ratio 1.18 ± 1.11 1.15 ± 1.06 0.817 0.546
Data are expressed as mean ± SD; the nonparametric Mann-Whitney test was used to compare the two groups. 
P-values adjusted for age and sex were obtained by general linear models.
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the two cholesterol efflux pathways contributing to total 
CEC, we found that AD was remarkably reduced in APR 
patients as compared with controls (25.5%; Fig. 1B), 
whereas ABCA1-mediated CEC did not significantly differ 
between groups (Fig. 1C). As for total CEC, the difference 
in AD CEC between APR and control groups remained sig-
nificant after adjusting for age, gender, and HDL-C levels 
(Model 3, Table 5). HDL CEC via the SR-BI and ABCG1 
transporters was also impaired in subjects with APR, with 
SR-BI being reduced to greater extent (41.1% and 30.4% 
for SR-BI and ABCG1, respectively) (Fig. 2A, B). The differ-
ences in SR-BI- and ABCG1-mediated CEC between groups 
were significant both without and with adjustment for age 
and gender (Model 2, Table 5). After further adjustment 
for HDL-C levels, the difference between groups was lost 
for SR-BI-mediated CEC and conserved for the ABCG1 
pathway (Model 3, Table 5). Due to the small number of 
samples analyzed for CEC, sub-analysis for APR causes was 
not possible.
SAA content in HDL
The amount of SSA associated with HDL was signifi-
cantly increased in APR subjects compared with controls; 
median and interquartile range was 25.59 (9.8–117.1) and 
532 (69.19–2,322) in controls and APR, respectively (Fig. 3, 
P = 0.003). This difference remained significant after ad-
justment for age and gender (P = 0.004).
Relationship between inflammation, cholesterol synthesis, 
absorption, and HDL-related parameters
Finally, we looked at the possible relationship between the 
evaluated parameters. Analyzing controls and APR patients 
together, we found that the ABCG1-mediated CEC inversely 
correlated with the markers of inflammatory status (sup-
plemental Fig. S1). In addition, the inflammatory values 
ESR and CRP inversely correlated with medium-sized HDL 
particles (r = 0.336; P = 0.008). Finally, SAA levels in-
versely correlated with ABCG1-mediated CEC (supple-
mental Fig. S2). All these correlations were lost when 
the two groups were analyzed separately.
We did not find significant correlations between the 
markers of cholesterol synthesis or absorption and the in-
flammatory status, either considering all subjects together 
or separately analyzing the two groups (data not shown). 
We did not find significant correlations of inflammatory in-
dexes with HDL particle concentration, structure, and func-
tion in control subjects. However, some correlations were 
found within APR group (Table 6): CRP and ferritin levels 
inversely correlated with HDL-C, apoA-I, and with LpAI:A-II 
levels. In addition, CRP directly associated with large HDL 
levels and with HDL SAA content. Again, only in the APR 
group, we observed an inverse and significant correla-
tion between SR-BI-mediated CEC and body temperature 
(r = 0.566; P = 0.006, Table 6). Both SR-BI-mediated CEC 
and body temperature weakly correlated with plasma 
TABLE 4. HDL composition and size in control and APR subjects
Control Subjects APR Subjects P P Adjusted for Age and Gender
LpA-I (mg/dl) 47.00 ± 14.83 33.85 ± 11.53 <0.001 0.015
LpA-I:A-II (mg/dl) 89.04 ± 22.68 49.08 ± 25.47 <0.001 <0.001
Small HDL (%) 20.32 ± 6.90 19.49 ± 8.54 0.563 0.435
Medium HDL (%) 17.84 ± 3.87 15.97 ± 2.84 0.048 0.019
Large HDL (%) 61.84 ± 9.44 63.20 ± 13.35 0.204 0.172
Pre- HDL (%) 9.36 ± 5.24 6.94 ± 5.50 0.034 0.374
Data are expressed as mean ± SD; the nonparametric Mann-Whitney test was used to compare the two groups. 
P-values adjusted for age and sex were obtained by general linear models. P-values expressing significant differences 
are shown in bold.
Fig. 1. HDL CEC: total (A), AD (B), and ABCA1-mediated CEC 
(C). Values are expressed as a percentage of radioactive cholesterol 
in cell supernatants after 4 h of exposure to apoB-depleted sera 
from controls (n = 25) and APR subjects (n = 24) over total radioac-
tive cell cholesterol. Each point represents the mean CEC relative to 
a sample run in triplicate. Statistical significance was calculated by 
using a two-sided nonparametric Mann-Whitney test. ****P < 0.0001.
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HDL-C levels (r = 0.403, P = 0.051 and r = 0.239, P = 0.091 
for SR-BI CEC and body temperature, respectively) and 
more markedly with apoA-I levels (r = 0.7102; P = 0.0001 
and r = 0.299; P = 0.033 for SR-BI CEC and temperature, 
respectively).
We did not find any significant associations between the 
plasma markers of cholesterol synthesis and absorption 
and the HDL-related parameters except for an inverse cor-
relation observed in control subjects between campesterol 
and small and medium HDL (r = 0.4312; P = 0.045 and 
r = 0.4435; P = 0.0436 with small and medium HDL, respec-
tively), and a positive relationship with large HDL (r = 0.434; 
P = 0.044). These relationships were absent in APR subjects.
DISCUSSION
The present results show, for the first time, that APR, 
characterized by a strong alteration of quantitative lipid 
profile, is not accompanied by significant variations in ei-
ther cholesterol synthesis or absorption. Conversely, this 
condition is associated to HDL composition and size modi-
fications and to profound impairment of the HDL athero-
protective CEC.
The first aim of our study was to investigate whether an 
impaired balance between cholesterol synthesis and ab-
sorption could play a role in lipid serum level changes dur-
ing APR. In fact, the balance between hepatic cholesterol 
synthesis and intestinal cholesterol absorption, studied by 
quantifying the noncholesterol sterols, is lost in several 
pathologic conditions leading to dyslipidemia and in-
creased cardiovascular risk (4, 36). In general, inflamma-
tory stress has been associated with reduced total, LDL, and 
HDL cholesterolemia (2) and our data are in line with 
these modifications. However, available data on the mecha-
nisms by which inflammation affects cholesterol homeosta-
sis are conflicting; for example, the inflammatory cytokines 
TNF-, TNF-, IL-1, and IFN- have been shown to stimu-
late hepatic cholesterol synthesis in mice (37–39), whereas 
IL-1 inhibits cholesterol synthesis in human hepatoma 
HepG2 cells (40). Our in vivo human study indicates that 
impaired cholesterol synthesis is not involved in lipid profile 
alterations. Similarly, we found no differences in cholesterol 
absorption. This finding is somewhat surprising, as APR 
would be expect to be associated with a reduction in gut cho-
lesterol absorption, due to the limited food intake secondary 
to the inflammatory state, at least before medical interven-
tion. Thus, possible suggested mechanisms for APR-induced 
dyslipidemia could be an increased catabolism of cholesterol-
rich lipoproteins or their retention outside the plasma, rather 
than an effect on cholesterol synthesis or absorption (2).
Due to the beneficial properties of HDL with respect to 
cardiovascular protection, we focused on HDL level, com-
position, and function. We found an inverse relationship 
between APR HDL-C level and the inflammatory parame-
ters CRP and ferritin, consistent with previous findings 
(5, 8). The mechanisms leading to HDL-C level changes 
during APR are currently not fully understood, but several 
have been proposed: an increased hepatic scavenger recep-
tor expression, leading to an enhanced turnover of HDL 
(41); a suppressed expression of the hepatic ABCA1 trans-
porter, resulting in reduced HDL generation (42); a higher 
lipolytic activity of secretory phospholipase A2 (43); and an 
increase in HDL-associated SAA, enhancing HDL clear-
ance (44). The latter mechanism seems to be supported by 
the elevation of HDL-associated SAA in our APR subjects 
TABLE 5. HDL CEC in control and APR subjects
Control Subjects APR Subjects P
Model 1 Model 2 Model 3
Total CEC (%) 9.38 ± 1.26 7.68 ± 1.24 0.0001 0.0001 0.011
AD-CEC (%) 6.53 ± 1.03 4.86 ± 0.86 <0.0001 <0.0001 0.013
ABCA1-CEC (%) 2.84 ± 0.66 2.82 ± 1.32 0.881 0.772 0.370
SR-BI-CEC (%) 1.97 ± 0.64 1.16 ± 0.52 0.0001 0.0001 0.930
ABCG1-CEC (%) 5.85 ± 0.93 4.07 ± 1.16 <0.0001 <0.0001 <0.0001
Data are expressed as mean ± SD; Model 1: unadjusted; Model 2: adjusted for age and gender; Model 3: adjusted 
for age, gender, and HDL-C. Adjusted P-values were obtained by general linear models. P-values expressing significant 
differences are shown in bold.
Fig. 2. HDL CEC: SR-BI- (A) and ABCG1-mediated CEC (B). Val-
ues are expressed as a percentage of radioactive cholesterol in cell 
supernatants after 4/6 h of exposure to apoB-depleted sera from 
both controls (n = 25) and APR subjects (n = 24) over total radioac-
tive cell cholesterol. Each point represents the mean CEC relative to 
a sample run in triplicate. Statistical significance was calculated by 
using a two-sided nonparametric Mann-Whitney test. ****P < 0.0001.
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that was found directly correlated to CRP plasma concen-
tration, as previously reported (45, 46).
With respect to the structural changes, the present re-
sults are consistent with our previous findings obtained in 
patients with APR due to acute myocardial infarction and 
consisting of the reduction of medium-sized HDL contain-
ing both apoA-I and apoA-II (45, 47). These data indicate 
that HDL distribution into distinct subclasses for size and 
composition is similarly affected by APR, independently of 
the triggering event.
The inverse correlation that we observed between the 
inflammatory status (CRP level) and medium-sized HDL 
containing both apoA-I and apoA-II further supports the 
idea of a specific impact of inflammation on HDL sub-
class distribution. Notably, the decrease of HDL con-
taining both apoA-I and apoA-II was slightly more evident 
in the group of patients with APR related to infections 
in which the inflammatory status was relatively more 
pronounced.
We observed a profound impairment of HDL CEC in the 
APR group. CEC is a measure of HDL anti-atherogenic 
properties, recently identified as a cardiovascular risk bio-
marker and as a promising target for prevention and ther-
apy, independently of plasma HDL-C concentrations (48). 
Other studies already demonstrated an impairment of 
HDL CEC in several inflammatory diseases (13, 14, 35, 49). 
However, the novelty of our observation is that CEC is al-
tered in a heterogeneous group of patients, having only 
inflammatory status in common.
In detail, we observed a specific impairment of the total 
CEC, the parameter associated with prevalent atherosclerosis 
and incident cardiovascular events (50, 51). Unfortunately, 
cardiovascular risk-related parameters were not available in 
our patients, but it is well known that conditions associated 
to inflammation are characterized by high cardiovascular 
risk (52). Indeed, elevated levels of the acute phase pro-
teins, even for a limited span of time, are related to higher 
cardiovascular disease risk (53, 54). ABCA1-mediated CEC 
was not affected in our patients, consistent with previous 
results (6). The opposite finding of de La Llera Moya et al. 
(34) for this parameter may be due to the specificity of 
their research protocol, based on lipopolysaccharide (LPS) 
injection in healthy volunteers.
Fig. 3. HDL SAA content in controls (n = 25) and APR subjects 
(n = 24). Data are presented as mean ± SD. Statistical significance 
was calculated by using a two-sided nonparametric Mann-Whitney 
test. **P = 0.003
TABLE 6. Relationship between inflammatory parameters and HDL concentration, size, composition, and 
function in APR subjects
ESR CRP WBC Ferritin Temperature
HDL-C r = 0.103 r = 0.346 r = 0.016 r = 0.416 r = 0.239
P = 0.440 P = 0.008 P = 0.906 P = 0.002 P = 0.091
apoA-I r = 0.071 r = 0.485 r = 0.019 r = 0.344 r = 0.299
P = 0.596 P = 0.001 P = 0.887 P = 0.010 P = 0.033
LpA-I r = 0.052 r = 0.052 r = 0.005 r = 0.158 r = 0.035
P = 0.723 P = 0.728 P = 0.973 P = 0.300 P = 0.826
LpA-I:A-II r = 0.067 r = 0.587 r = 0.170 r = 0.310 r = 0.385
P = 0.653 P < 0.001 P = 0.248 P = 0.038 P = 0.013
Small HDL r = 0.035 r = 0.240 r = 0.130 r = 0.004 r = 0.066
P = 0.826 P = 0.136 P = 0.418 P = 0.979 P = 0.704
Medium HDL r = 0.089 r = 0.293 r = 0.148 r = 0.009 r = 0.123
P = 0.578 P = 0.067 P = 0.354 P = 0.959 P = 0.480
Large HDL r = 0.098 r = 0.336 r = 0.211 r = 0.106 r = 0.164
P = 0.531 P = 0.029 P = 0.175 P = 0.514 P = 0.333
pre HDL r = 0.0739 r = 0.185 r = 0.231 r = 0.088 r = 0.303
P = 0.634 P = 0.234 P = 0.131 P = 0.582 P = 0.065
Total CEC r = 0.048 r = 0.287 r = 0.053 r = 0.103 r = 0.182
P = 0.824 P = 0.183 P = 0.806 P = 0.647 P = 0.418
AD-CEC r = 0.188 r = 0.026 r = 0.019 r = 0.293 r = 0.231
P = 0.378 P = 0.907 P = 0.929 P = 0.186 P = 0.301
ABCA1-CEC r = 0.185 r = 0.355 r = 0.064 r = 0.225 r = 0.144
P = 0.386 P = 0.096 P = 0.765 P = 0.314 P = 0.523
SR-BI-CEC r = 0.039 r = 0.262 r = 0.003 r = 0.299 r = 0.566
P = 0.854 P = 0.226 P = 0.987 P = 0.177 P = 0.006
ABCG1-CEC r = 0.220 r = 0.061 r = 0.003 r = 0.094 r = 0.138
P = 0.301 P = 0.781 P = 0.989 P = 0.676 P = 0.539
SAA r = 0.046 r = 0.521 r = 0.299 r = 0.176 r = 0.421
P = 0.830 P = 0.011 P = 0.156 P = 0.434 P = 0.051
Relationship between parameters was calculated by nonparametric correlation (Spearman’s coefficient 
reported). Statistically significant relationships are indicated in bold.
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In our study, APR was characterized by a decrease in 
SR-BI- and ABCG1-mediated CEC. The SR-BI-mediated CEC 
impairment in APR is in accordance with the observation 
of de La Llera Moya et al. (34) on the LPS model. However, 
in our work, the differences in SR-BI CEC were lost after 
adjustment for HDL-C levels, confirming the strong depen-
dence of this parameter on serum HDL concentrations 
(13, 55). The reduction of ABCG1-mediated CEC that we 
observed in APR is consistent with previous observations in 
postoperative patients (6, 56) and in patients with auto-
immune diseases (13, 57). The statistical significance of 
ABCG1-mediated CEC reduction persisted after correction 
for HDL serum levels, consistent with the reported weak or 
absent relationship of this parameter to serum HDL-C lev-
els (13, 58). The impact of inflammation on this efflux 
pathway seems to be confirmed by the observation that 
methotrexate, an anti-inflammatory agent widely used in 
rheumatoid arthritis patients, improves ABCG1-mediated 
CEC (59). Further supporting this concept, we found a sig-
nificant correlation between this CEC pathway and CRP, 
ESR, and ferritin when analyzing all subjects of the study. 
Interestingly, in the paper by de La Llera Moya et al. (34), 
the LPS-induced inflammation did not associate with 
ABCG1-mediated CEC reduction. With the limitation of 
the very small number of samples analyzed for ABCG1-CEC 
in that work, both their data and ours suggest that the 
mechanisms inducing HDL dysfunction in patients with 
pathologic conditions in real life might be very complex. It 
may be hypothesized that the reduced total and ABCG1-
mediated CEC found in our patients is due to peculiar 
variations of HDL composition in terms of protein or phos-
pholipid cargo able to compromise the anti-atherogenic 
properties of HDL, including CEC through ABCG1 (11, 60). 
For example, the robust and inverse relationship that we 
found between HDL SAA and ABCG1-mediated CEC could 
reflect a cause-effect link between inflammation and this 
cell cholesterol efflux pathway. Further studies are needed 
to mechanistically explore this relationship.
The positive correlation detected between CRP and ma-
ture HDL particles seems to suggest a direct link between 
inflammation and HDL maturation, in contrast with previ-
ous observations (5). However, this correlation could be ex-
plained as a phenomenon secondary to the deprivation of 
small/medium HDL induced by inflammation. Indeed, total 
HDL levels are reduced proportionally to inflammation in-
dexes. In any case, mature HDL particles showed an intrinsic 
functional impairment as demonstrated by the reduced ca-
pacity to accept cholesterol from the ABCG1 transporter, 
even after adjusting for serum HDL-C concentration.
This study has some limitations. First, the sample size is 
small and the matching between cases and controls in 
terms of age and especially of gender is poor. The lack of 
differences between data without and with correction for 
age and gender suggests that differences in these variables 
do not significantly affect our results although we cannot 
totally exclude the presence of other residual confounding 
factors.
Notably, only pre HDLs appear to be dependent on age 
and gender, consistent with previous reports (61). Another 
possible limitation of the study is that some control subjects 
present cardiovascular risk factors, possibly influencing 
lipid metabolism. However, the main inclusion criterion 
for the recruitment of controls was the absence of inflam-
mation in a “real life” situation. Further studies comparing 
APR to healthy subjects are needed to confirm our data. 
Among the limitations of this study is also the use of an in-
direct method for cholesterol synthesis and absorption 
measurement. To increase reliability of the results, at least 
on cholesterol absorption, we followed the recommenda-
tion to use two markers, sitosterol and campesterol, instead 
of one (62). Our findings require further confirmation 
through the stable isotope technique (63).
In conclusion, we demonstrated that APR does not asso-
ciate with modifications in markers of cholesterol absorp-
tion and synthesis but with alterations of HDL metabolism 
and quality. In particular, we found changes in HDL struc-
ture and a marked impairment of the athero-protective 
cholesterol efflux-promoting function, independent of 
HDL-C reduction. Further studies are needed to elucidate 
the specific mechanisms underlying our findings.
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